Synopsis of recent research by authors named "Alwin Dr Huitema"
Alwin Dr Huitema’s research primarily focuses on maximizing the stability and utility of expensive monoclonal antibodies and anticancer medications, addressing both economic and clinical concerns in oncology pharmacy practices.
Recent findings highlight the prolonged stability of nivolumab and pembrolizumab, allowing for better management of resources and reducing waste through effective redispensing practices for oral anticancer medicines.
Additionally, Dr. Huitema has developed innovative methodologies for monitoring drug concentrations using liquid chromatography-tandem mass spectrometry (LC-MS/MS), aiming to enhance therapeutic drug monitoring practices in various patient populations.